# Human Rating Form — GDgpt Clinical Utility Evaluation

> **Instructions**: Rate each question on D1-D5 (1=Poor, 3=Adequate, 5=Excellent).
> Fill in the table below. Use same rubric as the LLM judge.
> Return this file after completion.

## Rubric Summary
- **D1 Factual Accuracy**: Are gene/pathway/drug claims correct?
- **D2 Completeness**: Are key evidence items covered?
- **D3 Traceability**: Are claims attributed to specific sources/edges?
- **D4 Clinical Safety**: Does it acknowledge uncertainty vs. fabricate?
- **D5 Coherence**: Is it logically structured and readable?

---
## Question 1: `ind_dc_894be162ddbb`
**Q**: What genes and pathways are associated with hereditary breast ovarian cancer syndrome? What are the key mechanisms?

### System A (GDgpt)
```
** Hereditary breast ovarian cancer syndrome (HBOC) is primarily driven by BRCA1, which is ASSOCIATED_WITH hereditary breast ovarian cancer syndrome and INVOLVED_IN DNA repair pathways, including defective DNA double strand break response due to BRCA1 loss of function and the G2/M DNA damage checkpoint, as confirmed by the knowledge graph. Dysregulated signaling pathways such as the RAF/MAP kinase cascade (INVOLVED_IN by KIT, ERBB2, and FGF4) and PI3K/AKT signaling (INVOLVED_IN by KIT, ERBB2, ESR1, and AKT1) promote tumor survival and proliferation. Immune modulation through interleukin signaling pathways, such as Interleukin-4 and Interleukin-13 signaling (INVOLVED_IN by NOS2, ALOX5, and PTGS2), and inflammatory processes like neutrophil degranulation (INVOLVED_IN by ALOX5 and GSTP1), may
```

### System B (GPT-4o)
```
Hereditary Breast Ovarian Cancer (HBOC) syndrome is primarily associated with pathogenic variants in the **BRCA1** and **BRCA2** genes, which are tumor suppressor genes critical for DNA damage repair. Mutations in these genes disrupt the homologous recombination (HR) repair pathway, leading to genomic instability and increased cancer risk. Other genes involved in HBOC syndrome include **PALB2**, **RAD51C**, **RAD51D**, and **BRIP1**, which also play roles in DNA repair.

### Key Pathways and Mechanisms:
1. **Homologous Recombination DNA Repair Deficiency (HRD):**
   - BRCA1 and BRCA2 are essential for error-free repair of double-strand DNA breaks via homologous recombination.
   - Loss-of-function mutations in these genes lead to HRD, forcing cells to rely on error-prone repair pathways, s
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 2: `ind_dc_22d4a0eb6658`
**Q**: What genes and pathways are associated with hereditary breast carcinoma? What are the key mechanisms?

### System A (GDgpt)
```
Hereditary breast carcinoma is ASSOCIATED_WITH dysregulation of ATP-binding cassette (ABC) transporter genes, including ABCA3, ABCA4, ABCB1, and ABCB10, which are INVOLVED_IN lipid transport and cellular homeostasis per the knowledge graph. Dysregulation of these genes may influence tumorigenesis through disrupted energy regulation or membrane dynamics. The disease is also ASSOCIATED_WITH key signaling pathways, such as Estrogen-dependent gene expression (INVOLVING ESR1, BCL2, PGR, CCND1, JUN), PIP3 activates AKT signaling (INVOLVING KIT, ERBB2, ESR1, FGF4, AKT1), and the RAF/MAP kinase cascade (INVOLVING KIT, ERBB2, FGF4, GRIN2D, FGFR2), which drive tumorigenesis, cell proliferation, and survival. Additionally, immune-related pathways, including Interleukin-4 and Interleukin-13 signaling 
```

### System B (GPT-4o)
```
Hereditary breast carcinoma is primarily associated with germline mutations in genes involved in DNA damage repair and cell cycle regulation. The following genes and pathways are most commonly implicated:

### **Key Genes:**
1. **BRCA1 and BRCA2:** 
   - These are tumor suppressor genes crucial for homologous recombination (HR)-mediated DNA repair.
   - Mutations lead to defective DNA repair, genomic instability, and increased risk of breast and ovarian cancers.
   
2. **TP53:**
   - Encodes the p53 protein, a key regulator of cell cycle arrest, apoptosis, and DNA repair.
   - Germline mutations cause Li-Fraumeni syndrome, significantly increasing breast cancer risk.

3. **PTEN:**
   - Mutations are associated with Cowden syndrome, a condition characterized by a high risk of breast cancer 
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 3: `ind_dc_87845f398756`
**Q**: What genes and pathways are associated with breast neoplasm? What are the key mechanisms?

### System A (GDgpt)
```
** Breast neoplasm is mechanistically linked to dysregulation of key genes and pathways, supported by robust knowledge graph (KG) evidence. The ABC transporter gene family, including **ABCA3**, **ABCA4**, **ABCB1**, and **ABCB10**, is ASSOCIATED_WITH breast neoplasm, with **ABCB1** INTERACTING_WITH the **ABC-family proteins mediated transport** and **Abacavir transmembrane transport** pathways, suggesting a role in chemoresistance. Hormone receptor signaling is implicated via the **Estrogen-dependent gene expression** pathway, where **ESR1**, **BCL2**, **PGR**, **CCND1**, and **JUN** are ASSOCIATED_WITH breast neoplasm and INTERACT_WITH this pathway, promoting tumor cell proliferation in hormone receptor-positive breast cancer. Dysregulation of growth factor signaling is evident through th
```

### System B (GPT-4o)
```
Breast neoplasms are associated with several key genes and pathways that drive tumorigenesis, progression, and therapeutic resistance. Below is a concise outline of the most relevant genes, pathways, and mechanisms:

### **Genes Frequently Associated with Breast Neoplasm:**
1. **Tumor Suppressor Genes:**
   - **TP53**: Regulates cell cycle arrest, apoptosis, and DNA repair. Mutations are common in triple-negative breast cancer (TNBC).
   - **BRCA1/BRCA2**: Critical for homologous recombination (HR) DNA repair. Germline mutations increase the risk for hereditary breast and ovarian cancer syndromes.
   - **PTEN**: Regulates PI3K/AKT signaling and cell survival. Loss of PTEN is associated with aggressive phenotypes.

2. **Oncogenes:**
   - **PIK3CA**: Activates the PI3K/AKT/mTOR pathway, prom
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 4: `ind_dc_2000b5e3f24d`
**Q**: What genes and pathways are associated with squamous cell carcinoma of the corpus uteri? What are the key mechanisms?

### System A (GDgpt)
```
**  
Squamous cell carcinoma of the corpus uteri is ASSOCIATED_WITH dysregulation of ATP-binding cassette (ABC) transporter genes, including **ABCA3**, **ABCA4**, **ABCB1**, and **ABCB10**, which are INVOLVED_IN pathways such as **ABC transporters in lipid homeostasis** and **Defective ABCA3 causes SMDP3** per the knowledge graph. Dysregulation of these genes may contribute to chemoresistance and altered tumor metabolism. Additionally, **NOS2, PTGS2, HMOX1, MAOA**, and **MMP9** are INVOLVED_IN the **Interleukin-4 and Interleukin-13 signaling** pathway, which modulates immune response and chronic inflammation, potentially creating a tumor-promoting microenvironment. Hormonal signaling is implicated through **ESR1, BCL2, PGR, CCND1**, and **JUN**, which are INVOLVED_IN the **Estrogen-depende
```

### System B (GPT-4o)
```
Squamous cell carcinoma of the corpus uteri is a rare subtype of endometrial cancer, and its molecular characterization is not as well-defined as other histologic types, such as endometrioid or serous endometrial carcinomas. However, based on existing knowledge, the following genes and pathways have been implicated:

### Key Genes:
1. **TP53**: Mutations in TP53 are commonly associated with aggressive features and poor prognosis in endometrial carcinomas, including rare squamous cell variants.
2. **PIK3CA** and **PTEN**: Alterations in the PI3K/AKT/mTOR signaling pathway are frequently seen in endometrial cancers, including squamous and mixed histologies.
3. **KRAS**: Mutations in KRAS may contribute to tumorigenesis in certain variants of endometrial cancers.
4. **CDKN2A (p16)**: Loss of 
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 5: `ind_dc_efd557a940d1`
**Q**: What genes and pathways are associated with undifferentiated carcinoma of the corpus uteri? What are the key mechanisms?

### System A (GDgpt)
```
The knowledge graph confirms that the ATP-binding cassette (ABC) transporter genes **ABCA3**, **ABCA4**, **ABCB1**, and **ABCB10** are ASSOCIATED_WITH undifferentiated carcinoma of the corpus uteri. Among these, **ABCA3** is INVOLVED_IN the **ABC transporters in lipid homeostasis pathway** and the **Defective ABCA3 causes SMDP3 pathway**, suggesting potential lipid dysregulation in the tumor microenvironment. Additionally, the **Estrogen-dependent gene expression pathway**, which involves **ESR1**, **BCL2**, and **PGR**, highlights the role of hormonal signaling in uterine cancer. Oncogenic pathways such as **PIP3 activates AKT signaling** (involving **KIT**, **ERBB2**, **ESR1**, **FGF4**, and **AKT1**) and the **RAF/MAP kinase cascade** (involving **KIT**, **ERBB2**, **FGF4**, **GRIN2D**,
```

### System B (GPT-4o)
```
Undifferentiated carcinoma of the corpus uteri is a rare and aggressive subtype of endometrial cancer characterized by high-grade histology and loss of differentiation. Its molecular mechanisms are not fully understood, but studies have identified several key genes and pathways associated with its pathogenesis:

### **Key Genes:**
1. **SWI/SNF Complex Genes**:
   - **SMARCA4**: Loss-of-function mutations in SMARCA4 (BRG1) are implicated in undifferentiated carcinoma, leading to defects in chromatin remodeling.
   - **ARID1A**: Mutations in ARID1A, another component of the SWI/SNF chromatin remodeling complex, are frequently seen in aggressive endometrial carcinomas.

2. **TP53**:
   - Mutations in TP53 are common in undifferentiated and high-grade endometrial carcinomas, leading to loss of
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 6: `ind_dc_182a1e726ac1`
**Q**: What genes and pathways are associated with schizophrenia? What are the key mechanisms?

### System A (GDgpt)
```
Schizophrenia is ASSOCIATED_WITH genetic susceptibility factors such as **A1BG**, **ABCA1**, **ABCA13**, and **ABCB1**, as confirmed by the knowledge graph. The disease is INVOLVED_IN multiple pathways, including the **RAF/MAP kinase cascade**, where genes like **GRIN1**, **GRIN2D**, and **GRIN2B** encode NMDA receptor subunits critical for synaptic plasticity and neuronal signaling. Dysregulation in this pathway may impair neural development and survival. Schizophrenia is also LINKED_TO the **G alpha (i) signalling events** pathway through genes such as **CNR1** and **GABBR1**, which are involved in GPCR-mediated neurotransmitter signaling, potentially contributing to synaptic communication deficits. The **Neutrophil degranulation** pathway, INTERACTING_WITH **ABCA13** and involving genes
```

### System B (GPT-4o)
```
Schizophrenia is a complex neuropsychiatric disorder with both genetic and environmental contributors. While no single gene is solely responsible, several genes and pathways have been implicated in its pathogenesis. Below is a concise summary of key genes, pathways, and mechanisms:

### Key Genes:
1. **COMT (Catechol-O-Methyltransferase):** Involved in dopamine metabolism; polymorphisms (e.g., Val158Met) may affect dopamine signaling in the prefrontal cortex.
2. **DISC1 (Disrupted in Schizophrenia 1):** Plays a role in neuronal development, synaptic signaling, and brain connectivity.
3. **NRG1 (Neuregulin 1):** Involved in synaptic plasticity and myelination.
4. **DRD2 (Dopamine D2 Receptor):** A key target of antipsychotic medications; altered dopamine receptor signaling is central to sch
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 7: `ind_dc_9c33ed784d74`
**Q**: What genes and pathways are associated with colorectal cancer? What are the key mechanisms?

### System A (GDgpt)
```
Colorectal cancer is ASSOCIATED_WITH key genes **A2M**, **ABCA1**, **ABCA10**, and **ABCA12**, with **A2M** playing a central role in tumor progression. Specifically, **A2M** is INVOLVED_IN the **Degradation of the extracellular matrix** pathway, which includes genes **MMP1**, **MMP2**, **MMP9**, and **MMP12**, facilitating tumor invasion and metastasis per the knowledge graph. Additionally, the **Neutrophil degranulation** pathway, linked to genes **ALOX5**, **LTF**, **MPO**, **GGH**, and **GALNS**, highlights the role of chronic inflammation in oncogenesis. The **Interleukin-4 and Interleukin-13 signaling** pathway, involving genes **NOS2**, **PTGS2**, and **VEGFA**, underscores immune modulation and angiogenesis in the tumor microenvironment. Furthermore, the **Ub-specific processing pr
```

### System B (GPT-4o)
```
Colorectal cancer (CRC) is associated with a complex interplay of genetic alterations and dysregulated signaling pathways. Key genes and pathways involved include:

### 1. **APC/β-Catenin (Wnt Signaling Pathway):**
   - **Genes:** APC (tumor suppressor), CTNNB1 (encodes β-catenin).
   - **Mechanism:** Loss-of-function mutations in APC lead to aberrant activation of Wnt signaling, allowing β-catenin to accumulate and translocate to the nucleus, where it drives transcription of oncogenic target genes like MYC and CCND1.

### 2. **TP53 (Tumor Suppressor Pathway):**
   - **Gene:** TP53.
   - **Mechanism:** Mutations in TP53 disrupt cell cycle arrest, apoptosis, and DNA repair, promoting genomic instability and tumor progression.

### 3. **KRAS/NRAS and MAPK Pathway:**
   - **Genes:** KRAS, NRA
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 8: `ind_dc_6847df815fd5`
**Q**: What genes and pathways are associated with familial prostate carcinoma? What are the key mechanisms?

### System A (GDgpt)
```
** Familial prostate carcinoma is ASSOCIATED_WITH multiple genes, including **ALOX5**, **AKT1**, **EGFR**, **AAAS**, **ABCC4**, **ABCG5**, and **ABO**, as confirmed by the knowledge graph. Mechanistically, **ALOX5** is INVOLVED_IN the **Neutrophil degranulation pathway** and the **Interleukin-4 and Interleukin-13 signaling pathway**, both of which are implicated in inflammatory responses, immune modulation, and tumor microenvironment remodeling. **AKT1** is INVOLVED_IN the **PI5P, PP2A, and IER3 regulate PI3K/AKT signaling pathway** and the **PIP3 activates AKT signaling pathway**, which are central to cell proliferation, survival, and resistance to apoptosis. **EGFR** is INVOLVED_IN the **RAF/MAP kinase cascade**, a pathway critical for cell growth and differentiation. These pathways coll
```

### System B (GPT-4o)
```
Familial prostate carcinoma is associated with several genes and pathways that influence hereditary predisposition and tumorigenesis. Key genes and mechanisms include:

### **Genes and Pathways**
1. **DNA Damage Repair Pathways**
   - **BRCA1/BRCA2**: Mutations in these genes, primarily known for their role in breast and ovarian cancers, are also implicated in prostate cancer, especially aggressive forms. They impair homologous recombination repair of DNA damage, leading to genomic instability.
   - **ATM**: A gene involved in DNA damage response. Loss-of-function mutations in ATM can lead to defective repair mechanisms and increased cancer risk.
   - **CHEK2**: Encodes a checkpoint kinase involved in DNA repair. Mutations in CHEK2 are linked to familial prostate cancer due to impaired cel
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 9: `ind_dc_d746db37c9cf`
**Q**: What genes and pathways are associated with prostate cancer? What are the key mechanisms?

### System A (GDgpt)
```
Prostate cancer is ASSOCIATED_WITH dysregulation across multiple molecular pathways, as confirmed by the knowledge graph (KG). Key genes such as **ERBB2, AKT1, EGFR, ESR1, ESR2** are INVOLVED_IN the **PI3K/AKT signaling** pathway (PI5P, PP2A, and IER3 regulate PI3K/AKT signaling; PIP3 activates AKT signaling), which is critical for tumor cell survival, proliferation, and resistance to apoptosis. Additionally, **ERBB2, EGFR, MET, EGF, PIK3R1** are INVOLVED_IN the **RAF/MAP kinase cascade**, a pathway essential for tumor growth and progression via growth factor signaling. Immune-related pathways also play a role, with **B2M, ALOX5, GSTP1, CTSB, MME** ASSOCIATED_WITH the **Neutrophil degranulation** pathway, likely contributing to inflammation-mediated tumor microenvironment alteration. Furth
```

### System B (GPT-4o)
```
Prostate cancer is associated with several genes and pathways that are implicated in tumor initiation, progression, and resistance to therapy. Below is a concise summary:

### Key Genes Associated with Prostate Cancer:
1. **Androgen Receptor (AR)**: Central to prostate cancer. AR signaling drives tumor growth in androgen-sensitive disease and remains active in castration-resistant prostate cancer (CRPC).
2. **PTEN**: Loss of this tumor suppressor gene leads to activation of the PI3K/AKT/mTOR pathway, promoting cell survival and proliferation.
3. **TP53**: Mutations in this tumor suppressor gene are associated with aggressive prostate cancer phenotypes and resistance to treatment.
4. **RB1**: Alterations in RB1 are linked to progression to CRPC and neuroendocrine prostate cancer.
5. **BRCA1
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 10: `ind_dc_3bb0a1cdbe69`
**Q**: What genes and pathways are associated with hepatocellular carcinoma? What are the key mechanisms?

### System A (GDgpt)
```
Hepatocellular carcinoma is ASSOCIATED_WITH multiple genes and pathways, as confirmed by the knowledge graph. Key mechanisms include immune and inflammatory dysregulation, chromosomal instability, extracellular matrix remodeling, and cytoskeletal dynamics. Specifically, SERPINA1 and GSTP1 are INTERACTS_WITH the Neutrophil degranulation pathway, which involves immune dysregulation and inflammatory responses critical to liver damage and hepatocellular carcinoma progression. CDK1, AURKB, and PLK1 are INTERACTS_WITH the Resolution of Sister Chromatid Cohesion pathway, where dysregulation leads to chromosomal instability, a hallmark of cancer promoting uncontrolled hepatocyte proliferation. A2M is INTERACTS_WITH the Degradation of the extracellular matrix pathway, facilitating tumor invasion an
```

### System B (GPT-4o)
```
Hepatocellular carcinoma (HCC) is associated with several genetic alterations and pathways that drive tumor development and progression. Below is a summary of key genes, pathways, and mechanisms involved:

### 1. **Key Genes Associated with HCC**
   - **TP53**: Frequently inactivated in HCC, leading to loss of cell cycle regulation and genomic instability.
   - **CTNNB1 (β-catenin)**: Activating mutations result in constitutive activation of the Wnt/β-catenin signaling pathway, promoting cell proliferation and survival.
   - **TERT (telomerase reverse transcriptase)**: Promoter mutations upregulate telomerase activity, leading to immortalization of cancer cells.
   - **AXIN1**: Mutations in this negative regulator of Wnt signaling enhance β-catenin activity.
   - **ARID1A/ARID2**: Loss-of-
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 11: `ind_dc_c36faf6ef60d`
**Q**: What genes and pathways are associated with liver cancer? What are the key mechanisms?

### System A (GDgpt)
```
Liver cancer demonstrates a multifaceted mechanism involving genetic and pathway-level dysregulation. The knowledge graph confirms that **A2M**, **AADAT**, **ABCB1**, and **ABCB4** are ASSOCIATED_WITH liver cancer, with **A2M** INVOLVED_IN pathways such as **Degradation of the extracellular matrix**, **HDL assembly**, and **Intrinsic Pathway of Fibrin Clot Formation**, suggesting roles in extracellular matrix remodeling, lipid metabolism, and thrombosis. Additionally, genes such as **SERPINA1**, **LTF**, **FABP5**, **GSTP1**, and **HPSE** are ASSOCIATED_WITH liver cancer and INTERACT_WITH the **Neutrophil degranulation** pathway, indicating contributions to chronic inflammation and immune dysregulation. Dysregulation of cell cycle pathways, including **Resolution of Sister Chromatid Cohesi
```

### System B (GPT-4o)
```
Liver cancer, primarily hepatocellular carcinoma (HCC), is associated with several key genes and pathways that regulate cell proliferation, survival, and genomic stability. Below are the major genes, pathways, and mechanisms involved:

### Key Genes:
1. **TP53**: Frequently mutated in HCC, leading to loss of tumor suppressor function and genomic instability.
2. **CTNNB1 (β-catenin)**: Activating mutations in CTNNB1 drive aberrant Wnt/β-catenin signaling, promoting proliferation.
3. **TERT (Telomerase Reverse Transcriptase)**: Promoter mutations increase telomerase activity, contributing to cellular immortality.
4. **AXIN1**: Inactivating mutations impair Wnt/β-catenin pathway regulation.
5. **ARID1A/ARID2**: Epigenetic regulators involved in chromatin remodeling, often mutated, leading to 
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 12: `ind_dc_dbb1afa7f685`
**Q**: What genes and pathways are associated with lung cancer? What are the key mechanisms?

### System A (GDgpt)
```
A2M, AATK, ABCB1, and ACE are ASSOCIATED_WITH lung cancer per the knowledge graph. The strongest mechanistic explanation involves the RAF/MAP kinase cascade, which is ASSOCIATED_WITH lung cancer through genes EGFR and MET and is INVOLVED_IN cell proliferation and survival, promoting tumor progression. Chronic inflammation and immune modulation are supported by the Interleukin-4 and Interleukin-13 signaling pathway, which is ASSOCIATED_WITH lung cancer through genes NOS2, ALOX5, HMOX1, MMP9, and VEGFA, and the Neutrophil degranulation pathway, which is ASSOCIATED_WITH lung cancer through genes ALOX5 and GSTP1. These pathways contribute to inflammation, oxidative stress, and angiogenesis, enhancing tumor microenvironment modulation. The PI3K/AKT signaling pathway, specifically the PI5P, PP2A
```

### System B (GPT-4o)
```
Lung cancer is associated with various genetic alterations and pathways that drive tumorigenesis, cell survival, and metastasis. Here is a concise summary of key genes, pathways, and mechanisms:

### Key Genes:
1. **Oncogenes:**
   - **EGFR**: Mutations (e.g., exon 19 deletions, exon 21 L858R) lead to constitutive activation of the EGFR signaling pathway.
   - **KRAS**: Mutations (e.g., G12C, G12D) are common in lung adenocarcinomas and activate downstream signaling pathways.
   - **ALK**: Rearrangements (e.g., EML4-ALK fusions) result in constitutive kinase activity.
   - **ROS1**: Fusions (e.g., CD74-ROS1) activate oncogenic signaling.
   - **MET**: Amplifications or exon 14 skipping mutations enhance MET signaling.
   - **BRAF**: V600E mutations lead to constitutive activation of the MA
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 13: `ind_dc_d130a7eb1f15`
**Q**: What genes and pathways are associated with adenocarcinoma of liver and intrahepatic biliary tract? What are the key mechanisms?

### System A (GDgpt)
```
Adenocarcinoma of the liver and intrahepatic biliary tract is ASSOCIATED_WITH the genes **A2M**, **AADAT**, **ABCB1**, **ABCB4**, **CDK1**, **AURKB**, **BIRC5**, **CENPE**, and **PLK1**, as confirmed by the knowledge graph. These genes are INVOLVED_IN pathways critical to cancer progression, including **Resolution of Sister Chromatid Cohesion**, **Separation of Sister Chromatids**, **RHO GTPases Activate Formins**, **Neutrophil Degranulation**, and **Degradation of the Extracellular Matrix**. Mechanistically, chromosomal instability is driven by dysregulation of pathways such as **Resolution of Sister Chromatid Cohesion** and **Amplification of Signal from Unattached Kinetochores via a MAD2 Inhibitory Signal**, involving genes like **CDK1**, **AURKB**, **BIRC5**, **CENPE**, and **PLK1**. C
```

### System B (GPT-4o)
```
Adenocarcinoma of the liver and intrahepatic biliary tract (encompassing hepatocellular carcinoma [HCC] and intrahepatic cholangiocarcinoma [iCCA]) involves several genes and pathways that drive tumorigenesis. Below is a concise overview:

### 1. **Hepatocellular Carcinoma (HCC)**
   - **Key Genes**:
     - **TP53**: Frequently mutated, leading to loss of tumor suppressor function.
     - **CTNNB1 (β-catenin)**: Mutations drive Wnt/β-catenin pathway activation.
     - **TERT**: Promoter mutations result in telomerase activation and genomic stability.
     - **AXIN1**: Mutations impair Wnt pathway regulation.
     - **ARID1A/ARID2**: Chromatin remodeling gene mutations contribute to epigenetic dysregulation.
   
   - **Key Pathways**:
     - **Wnt/β-catenin pathway**: Aberrant activation pr
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 14: `ind_dc_8df2021cf75b`
**Q**: What genes and pathways are associated with undifferentiated carcinoma of liver and intrahepatic biliary tract? What are the key mechanisms?

### System A (GDgpt)
```
The undifferentiated carcinoma of the liver and intrahepatic biliary tract is ASSOCIATED_WITH key genes **A2M**, **AADAT**, **ABCB1**, and **ABCB4** per the knowledge graph. **A2M** is INVOLVED_IN pathways such as **Degradation of the extracellular matrix**, **HDL assembly**, and **Intrinsic Pathway of Fibrin Clot Formation**, suggesting roles in extracellular matrix remodeling, lipid metabolism, and fibrin deposition, which are critical for tumor invasion, metastasis, and angiogenesis. **ABCB1** is ASSOCIATED_WITH multidrug resistance, indicating a potential mechanism of chemoresistance, while **ABCB4** is ASSOCIATED_WITH bile salt transport, implicating bile metabolism dysregulation in this cancer. **AADAT** is ASSOCIATED_WITH amino acid metabolism, which may contribute to metabolic dysr
```

### System B (GPT-4o)
```
Undifferentiated carcinoma of the liver and intrahepatic biliary tract is rare, and its molecular underpinnings are not fully characterized. However, based on available data, key genes and pathways potentially associated with this tumor type include:

### Associated Genes:
1. **TP53**: Frequently mutated in poorly differentiated or aggressive liver and biliary tract cancers, leading to impaired DNA damage response and cell cycle regulation.
2. **KRAS**: Activating mutations in KRAS are common in intrahepatic cholangiocarcinoma, driving growth and proliferation through MAPK/ERK signaling.
3. **IDH1/IDH2**: Mutations in these genes are seen in cholangiocarcinoma, resulting in abnormal 2-hydroxyglutarate production and epigenetic dysregulation.
4. **FGFR2**: Fusions in FGFR2 are specifically 
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |

---
## Question 15: `ind_dc_f30ad13c7079`
**Q**: What genes and pathways are associated with squamous cell carcinoma of liver and intrahepatic biliary tract? What are the key mechanisms?

### System A (GDgpt)
```
Squamous cell carcinoma of the liver and intrahepatic biliary tract is ASSOCIATED_WITH multiple genes and pathways per the knowledge graph. **A2M** is ASSOCIATED_WITH the disease and INVOLVED_IN pathways such as **Degradation of the Extracellular Matrix**, **HDL Assembly**, and **Intrinsic Pathway of Fibrin Clot Formation**, suggesting extracellular matrix remodeling as a mechanism of tumor progression. **CDK1, AURKB, BIRC5, CENPE, and PLK1** are ASSOCIATED_WITH the disease and INVOLVED_IN pathways like **Resolution of Sister Chromatid Cohesion** and **Separation of Sister Chromatids**, implicating chromosomal instability as a driver of cancer progression. **RAC1, AURKB, BIRC5, CENPE, and PLK1** are INVOLVED_IN the pathway **RHO GTPases Activate Formins**, highlighting cytoskeletal dynamic
```

### System B (GPT-4o)
```
Squamous cell carcinoma (SCC) of the liver and intrahepatic biliary tract is an extremely rare malignancy, and its molecular mechanisms are not well characterized. However, based on existing knowledge from biliary tract cancers and SCCs in other sites, several genes and pathways may be implicated:

### Key Genes and Pathways:
1. **TP53**: Mutations in TP53 are frequently observed in biliary tract cancers and SCCs, leading to loss of cell cycle regulation and genomic instability.

2. **KRAS**: Mutations in KRAS are common in biliary tract cancers and may play a role in SCC transformation by activating the MAPK/ERK signaling pathway.

3. **PIK3CA/AKT/mTOR Pathway**: Dysregulation of this pathway, through PIK3CA mutations or PTEN loss, is implicated in various SCCs and biliary tract malignanc
```

### Your Ratings

| Dimension | System A score (1/3/5) | System B score (1/3/5) | Notes |
|---|---|---|---|
| D1 Factual Accuracy | | | |
| D2 Completeness | | | |
| D3 Traceability | | | |
| D4 Clinical Safety | | | |
| D5 Coherence | | | |
